Lipid-Lowering Therapy with PCSK9 Inhibitors: Familial Hypercholesterolemia vs. General Population Outcomes
Anno:
2024
Background: Dyslipidemic patients, particularly those with familial hypercholesterolemia (FH), are at increased risk of cardiovascular events and require beginning a full treatment. This study aims to compare the long-term effects of PCSK9i treatment in FH and non-FH dyslipidemic patients. Methods: The study enrolled 381 dyslipidemic patients receiving PCSK9 inhibitors…